Induction of long-term tolerance to a specific antigen using anti-CD3 lipid nanoparticles following gene therapy

Development of factor VIII (FVIII) inhibitors is a serious complication in the treatment of hemophilia A (HemA) patients. In clinical trials, anti-CD3 antibody therapy effectively modulates the immune response of allograft rejection or autoimmune diseases without eliciting major adverse effects. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chun-Yu, Vander Kooi, Amber, Cavedon, Alex, Cai, Xiaohe, Hoggatt, Jonathan, Martini, Paolo G.V., Miao, Carol H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618827/
https://www.ncbi.nlm.nih.gov/pubmed/37920545
http://dx.doi.org/10.1016/j.omtn.2023.102043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618827/
https://www.ncbi.nlm.nih.gov/pubmed/37920545
http://dx.doi.org/10.1016/j.omtn.2023.102043

Ejemplares similares